Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

REGENERON PHARMACEUTICALS INC

Form 4 April 26, 2007

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB 3235-0287 Number:

Check this box if no longer subject to Section 16.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

January 31, Expires: 2005

0.5

OMB APPROVAL

Form 4 or Form 5 obligations may continue.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

Estimated average burden hours per response...

See Instruction

1(b).

(Print or Type Responses)

1. Name and Addi GOLDBERG	•	_	2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS INC [REGN]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner		
(Last) 777 OLD SAW	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 04/25/2007	X Officer (give title Other (specify below) SVP Fin & Admin, CFO, & Treas		
ROAD		Lix	04/23/2007			
	(Street)		4. If Amendment, Date Original	6. Individual or Joint/Group Filing(Check		
TARRYTOWN, NY 10591		1	Filed(Month/Day/Year)	Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person		

(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

		1 401	CI-Non-D	ciivative	occuri	nes Acqu	irea, Disposea or	, or beneficial	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactio Code (Instr. 8)	4. Securities Acquired on(A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code V	Amount	or (D)	Price	(Instr. 3 and 4)		
Common Stock	04/25/2007		M(1)	16,189	A	\$ 8.77	54,967	D	
Common Stock	04/25/2007		F(1)	5,289	D	\$ 26.84	49,678	D	
Common Stock	04/25/2007		F(1)	3,683	D	\$ 26.84	45,995	D	
Common Stock	04/25/2007		M <u>(1)</u>	4,000	A	\$ 9.49	49,995	D	
	04/25/2007		F(1)	1,413	D		48,582	D	

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Common Stock					\$ 26.84		
Common Stock	04/25/2007	F(1)	873	D	\$ 26.84	47,709	D
Common Stock	04/26/2007	S(1)	911	D	\$ 27	46,798	D
Common Stock	04/26/2007	S(1)	159	D	\$ 27.01	46,639	D
Common Stock	04/26/2007	S(1)	2,172	D	\$ 27.03	44,467	D
Common Stock	04/26/2007	S(1)	600	D	\$ 27.04	43,867	D
Common Stock	04/26/2007	S <u>(1)</u>	1,589	D	\$ 27.05	42,278	D
Common Stock	04/26/2007	S(1)	733	D	\$ 27.07	41,545	D
Common Stock	04/26/2007	S(1)	267	D	\$ 27.08	41,278	D
Common Stock	04/26/2007	S(1)	1,000	D	\$ 27.1	40,278	D
Common Stock	04/26/2007	S(1)	100	D	\$ 27.15	40,178	D
Common Stock	04/26/2007	S(1)	200	D	\$ 27.17	39,978	D
Common Stock	04/26/2007	S(1)	100	D	\$ 27.22	39,878	D
Common Stock	04/26/2007	S(1)	700	D	\$ 27.25	39,178	D
Common Stock	04/26/2007	S(1)	100	D	\$ 27.26	39,078	D
Common Stock	04/26/2007	S(1)	24	D	\$ 27.29	39,054	D
Common Stock	04/26/2007	S <u>(1)</u>	100	D	\$ 27.3	38,954	D
Common Stock	04/26/2007	S(1)	76	D	\$ 27.35	38,878	D
Common Stock	04/26/2007	S(1)	100	D	\$ 27.39	38,778	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not

SEC 1474 (9-02)

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of onDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		Underlying S	. Title and Amour Jnderlying Securit Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amo or Num of Sh	
Non-Qualified Stock Option (right to buy)	\$ 8.77	04/25/2007		M <u>(1)</u>	16,189	(2)	12/20/2009	Common Stock	16,	
Non-Qualified Stock Option (right to buy)	\$ 9.49	04/25/2007		M <u>(1)</u>	4,000	<u>(4)</u>	12/15/2014	Common Stock	4,0	

Reporting Owners

Reporting Owner Name / Address	Relationships							
• 9	Director	10% Owner	Officer	Other				
GOLDBERG MURRAY A			SVP Fin &					
777 OLD SAW MILL RIVER ROAD			Admin, CFO,					
TARRYTOWN, NY 10591			& Treas					

Signatures

/s/**Murray A.
Goldberg

**Signature of Reporting

Date

Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- (2) The stock option becomes exercisable in five equal annual installments, commencing one year after the date of grant.
- (3) Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is not applicable in this case.
- (4) The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Reporting Owners 3

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.